Your browser doesn't support javascript.
loading
Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma.
Zacarías-Fluck, Mariano F; Massó-Vallés, Daniel; Giuntini, Fabio; González-Larreategui, Íñigo; Kaur, Jastrinjan; Casacuberta-Serra, Sílvia; Jauset, Toni; Martínez-Martín, Sandra; Martín-Fernández, Génesis; Serrano Del Pozo, Erika; Foradada, Laia; Grueso, Judit; Nonell, Lara; Beaulieu, Marie-Eve; Whitfield, Jonathan R; Soucek, Laura.
Afiliación
  • Zacarías-Fluck MF; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; lsoucek@vhio.net mzacarias@vhio.net.
  • Massó-Vallés D; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Giuntini F; Peptomyc SL, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.
  • González-Larreategui Í; Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
  • Kaur J; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Casacuberta-Serra S; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Jauset T; Department of Cellular Biology, Phisiology, and Immunology, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallés, Spain.
  • Martínez-Martín S; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Martín-Fernández G; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Serrano Del Pozo E; Peptomyc SL, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.
  • Foradada L; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Grueso J; Peptomyc SL, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.
  • Nonell L; Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
  • Beaulieu ME; Models of Cancer Therapies Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Whitfield JR; Peptomyc SL, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.
  • Soucek L; Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
Genes Dev ; 37(7-8): 303-320, 2023 04 01.
Article en En | MEDLINE | ID: mdl-37024284
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Melanoma Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Genes Dev Asunto de la revista: BIOLOGIA MOLECULAR Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Melanoma Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Genes Dev Asunto de la revista: BIOLOGIA MOLECULAR Año: 2023 Tipo del documento: Article